NUVATION BIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.1 USD | +3.68% |
|
+0.65% | +105.30% |
| May. 14 | Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours | MT |
| May. 14 | Nuvation Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 825K | Capitalization | 766M |
|---|---|---|---|---|---|
| Net income 2024 * | -76M | Net income 2025 * | -144M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 928 x |
| P/E ratio 2024 * |
-11.3
x | P/E ratio 2025 * |
-7.21
x | Employees | 159 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.5% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.68% | ||
| 1 week | +0.65% | ||
| 1 month | -3.12% | ||
| 3 months | +39.01% | ||
| 6 months | +133.08% | ||
| Current year | +105.30% |
1 week
2.84
3.18
1 month
2.843.55
Current year
1.434.16
1 year
0.954.16
3 years
0.9513.75
5 years
0.9515.23
10 years
0.9515.23
| Managers | Title | Age | Since |
|---|---|---|---|
David Hung
FOU | Founder | 67 | 18-03-19 |
Moses Makunje
DFI | Director of Finance/CFO | 46 | 20-06-30 |
Dong Fang Liu
CTO | Chief Tech/Sci/R&D Officer | 54 | 22-07-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Hung
FOU | Founder | 67 | 18-03-19 |
Kim Blickenstaff
BRD | Director/Board Member | 71 | 19-07-31 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 20-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 3.1 | +3.68% | 5,095,647 |
| 24-05-30 | 2.99 | +2.40% | 893,372 |
| 24-05-29 | 2.92 | -1.35% | 1,314,474 |
| 24-05-28 | 2.96 | -3.90% | 1,069,909 |
| 24-05-24 | 3.08 | -.--% | 781,218 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotes
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Calendar
2024-06-05
- Jefferies Global Healthcare Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.1
USD
Average target price
6.6
USD
Spread / Average Target
+112.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +105.30% | 766M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- NUVB Stock
